✦ LIBER ✦

Weekly administration of topotecan–paclitaxel as second-line treatment in ovarian cancer

✍ Scribed by G. P. Stathopoulos; N. A. Malamos; G. Aravantinos; S. Rigatos; Ch. Christodoulou; J. Stathopoulos; D. Skarlos

Publisher: Springer
Year: 2006
Tongue: English
Weight: 255 KB
Volume: 60
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-006-0383-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Weekly administration of topotecan and p

Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study

✍ George P. Stathopoulos; Sotiris K. Rigatos; Christos Christodoulou; Nikos A. Mal 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 182 KB

Markov-modeling for the administration o

Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma

✍ M. Hartmann; M. Fedders; A. Schneider; R. Kath; O. Camara; H. Oelschläger 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 259 KB

Markov-modeling for the administration o

✍ M. Fedders; M. Hartmann; A. Schneider; R. Kath; O. Camara; H. Oelschläger 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 100 KB

Second-line chemotherapy in small cell l

Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study

✍ G. P. Stathopoulos; Ch. Christodoulou; J. Stathopoulos; D. Skarlos; S. K. Rigato 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 192 KB

Doxifluridine combined with weekly pacli

Doxifluridine combined with weekly paclitaxel for second-line treatment in patients with gastric cancer resistant to TS-1

✍ Wataru Arai; Yoshinori Hosoya; Masanobu Hyodo; Hidenori Haruta; Kentaro Kurashin 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 246 KB

Efficacy of low-dose topotecan in second

Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma

✍ Bo Gronlund; Heine H. Hansen; Claus Høgdall; Svend A. Engelholm 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

## Abstract ## BACKGROUND The high incidence of dose‐limiting myelosuppresion using the U.S. Food and Drug Administration‐approved topotecan dose of 1.5 mg/m^2^ for 5 days every 3 weeks may have limited its utility in the treatment of patients with epithelial ovarian carcinoma. The objective of th